EGFR-TK Inhibitor

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism